Assessing immune response and safety of CLOS-COLI vaccine preveting diarrhea symptoms caused by Clostridium perfringens type C and E. coli in pigs

Abstract

Inactivated vaccine namely CLOS-COLI produced by Hanvet company, used to prevent necrotic enteritis caused by C. perfringens type C in sows and diarrhea, edema diseases caused by E. coli bacteria in piglets was tested for safety and immune response in the experimental animals as well
as in the pigs. The studied results showed that vaccine was safe when injected with 4 fold doses in the sows; the titer of anti-E. coli antibodies was 4-4.5 times higher than that of pre-immunization, the titer of anti-toxin C. perfringens type C reached 3.8-4.0 log2. The afficacy of CLOS-COLI vaccine in
preventing diseases caused by C. perfringens type C and E. coli bacteria was similar with afficacy of
the imported vaccine in the market